These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

69 related articles for article (PubMed ID: 773580)

  • 1. Antiarrhythmic effects of a lidocaine congener, tocainide, 2-amino-2',6'-propionoxylidide, in man.
    McDevitt DG; Nies AS; Wilkinson GR; Smith RF; Woosley RL; Oates JA
    Clin Pharmacol Ther; 1976 Apr; 19(4):396-402. PubMed ID: 773580
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical efficacy and pharmacokinetics of a new orally effective antiarrhythmic, tocainide.
    Winkle RA; Meffin PJ; Fitzgerald JW; Harrison DC
    Circulation; 1976 Dec; 54(6):885-9. PubMed ID: 791536
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Kinetics of the oral antiarrhythmic lidocaine congener, tocainide.
    Lalka D; Meyer MB; Duce BR; Elvin AT
    Clin Pharmacol Ther; 1976 Jun; 19(6):757-66. PubMed ID: 1269216
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Anti-arrhythmic effect of tocainide (lidocaine congener) on ventricular arrhythmias (author's transl)].
    Kuck KH; Hanrath P; Lubda J; Mathey D; Bleifeld W
    Dtsch Med Wochenschr; 1979 Nov; 104(48):1701-5. PubMed ID: 93043
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of tocainide and quinidine on premature ventricular contractions.
    Wasenmiller JE; Aronow WS
    Clin Pharmacol Ther; 1980 Oct; 28(4):431-5. PubMed ID: 6773715
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiarrhythmic and circulatory effects of Astra W36095, a new lidocaine-like agent.
    Coltart DJ; Berndt TB; Kernoff R; Harrison DC
    Am J Cardiol; 1974 Jul; 34(1):35-41. PubMed ID: 4835751
    [No Abstract]   [Full Text] [Related]  

  • 7. Antiarrhythmic efficacy, pharmacokinetics and clinical safety of tocainide in convalescent myocardial infarction patients.
    Klein MD; Levine PA; Ryan TJ
    Chest; 1980 Jun; 77(6):726-30. PubMed ID: 6772381
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tocainide. A review of its pharmacological properties and therapeutic efficacy.
    Holmes B; Brogden RN; Heel RC; Speight TM; Avery GS
    Drugs; 1983 Aug; 26(2):93-123. PubMed ID: 6411445
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tocainide kinetics after intravenous and oral administration in healthy subjects and in patients with acute myocardial infarction.
    Graffner C; Conradson TB; Hofvendahl S; Rydén L
    Clin Pharmacol Ther; 1980 Jan; 27(1):64-71. PubMed ID: 7351118
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The acute antiarrhythmic effects of droxicainide and lidocaine in unanesthetized dogs.
    Aberg G; Ronfeld R; Smith E
    J Cardiovasc Pharmacol; 1984; 6(2):355-60. PubMed ID: 6200728
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical pharmacokinetics of the newer antiarrhythmic agents.
    Gillis AM; Kates RE
    Clin Pharmacokinet; 1984; 9(5):375-403. PubMed ID: 6437721
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hemodynamic and antiarrhythmic effects of tocainide in patients with acute myocardial infarction.
    Nyquist O; Forssell G; Nordlander R; Schenck-Gustafsson K
    Am Heart J; 1980 Dec; 100(6 Pt 2):1000-5. PubMed ID: 6778186
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and pharmacokinetics of oral pirmenol, a new antiarrhythmic drug.
    Garg DC; Jallad NS; Singh S; Ng KF; Weidler DJ
    J Clin Pharmacol; 1988 Sep; 28(9):812-7. PubMed ID: 2466056
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Total suppression of ventricular arrhythmias by encainide. Pharmacokinetic and electrocardiographic characteristics.
    Roden DM; Reele SB; Higgins SB; Mayol RF; Gammans RE; Oates JA; Woosley RL
    N Engl J Med; 1980 Apr; 302(16):877-82. PubMed ID: 6767186
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tocainide therapy for refractory ventricular arrhythmias.
    Roden DM; Roden DM; Reele SB; Reele SB; Higgins SB; Higgins SB; Carr RK; Carr RK; Smith RF; Smith RF; Oates JA; Oates JA; Woosley RL; Woosley RL
    Am Heart J; 1980 Jul; 100(1):15-22. PubMed ID: 6770666
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Suppression of ventricular ectopic depolarizations by tocainide.
    Woosley RL; McDevitt DG; Nies AS; Smith RF; Wilkinson GR; Oates JA
    Circulation; 1977 Dec; 56(6):980-4. PubMed ID: 923067
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Open clinical studies at a referral center: chronic maintenance tocainide therapy in patients with recurrent sustained ventricular tachycardia refractory to conventional antiarrhythmic agents.
    Maloney JD; Nissen RG; McColgan JM
    Am Heart J; 1980 Dec; 100(6 Pt 2):1023-30. PubMed ID: 6778190
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of rifampin on tocainide pharmacokinetics in humans.
    Rice TL; Patterson JH; Celestin C; Foster JR; Powell JR
    Clin Pharm; 1989 Mar; 8(3):200-5. PubMed ID: 2495879
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improved therapy of myotonia with the lidocaine derivative tocainide.
    Rüdel R; Dengler R; Ricker K; Haass A; Emser W
    J Neurol; 1980; 222(4):275-8. PubMed ID: 6154787
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Acute and long-term antiarrhythmia effect of encainide in chronic atrial extrasystole].
    Thale J; Klein H; Shanks RG; Bender F
    Z Kardiol; 1985 Apr; 74(4):220-7. PubMed ID: 2408392
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.